Hepatocellular carcinoma--rising incidence, changing therapeutic strategies.
Despite considerable efforts no ideal treatment exists for HCC. The disease is usually detected late and few patients are candidates for potentially curative treatment options such as surgical resection or liver transplantation. Surgical resection is limited mostly by the impaired liver function in cirrhotic livers, whereas liver transplantation is limited by tumor size, multi-localized disease and, most important, by shortage of donor organs. TACE as a local ablative treatment is able to induce local disease control and to prolong survival and might even achieve survival similar to surgical resection. The high rates of recurrence of HCC after successful control of local tumor spread is the reason to consider that procedure as a non-curative treatment option. PEI and RFA are able to control local tumor growth, but cannot influence tumor recurrence or de novo tumor growth. Systemic therapies need to be investigated in large randomized trials, especially to evaluate the use of somatostain analogues, HMGCoA reductase inhibitors, or other drugs such as rapamycin or inhibitors of vascular endothelial growth factor (VEGF).
Müller
Christian
C
Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria. christian.j.mueller@meduniwien.ac.at
D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D003430:Cross-Sectional Studies; D006498:Hepatectomy; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D016031:Liver Transplantation; D012307:Risk Factors; D016896:Treatment Outcome